These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Systemic Therapy for Melanoma: ASCO Guideline Update Q and A. Sondak VK; Atkins MB; Messersmith H; Provenzano A; Seth R; Agarwala SS JCO Oncol Pract; 2024 Feb; 20(2):173-177. PubMed ID: 38039436 [TBL] [Abstract][Full Text] [Related]
7. Integrating Health Equity in the ASCO Guideline Agenda: Recommendations From Members of the Palliative Care Expert Panel. Rosa WE; Garcia CA; Mardones MA; Temin S; Sanders JJ JCO Oncol Pract; 2024 Aug; ():OP2400291. PubMed ID: 39133878 [No Abstract] [Full Text] [Related]
8. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G; J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518 [TBL] [Abstract][Full Text] [Related]
9. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
10. Metastatic Pancreatic Cancer: ASCO Guideline Update. Sohal DPS; Kennedy EB; Cinar P; Conroy T; Copur MS; Crane CH; Garrido-Laguna I; Lau MW; Johnson T; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Pant S; Shah MA; Sahai V; Uronis HE; Zaidi N; Laheru D J Clin Oncol; 2020 Sep; 38(27):3217-3230. PubMed ID: 32755482 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021. Turpin A; El Amrani M; Bachet JB; Pietrasz D; Schwarz L; Hammel P Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371464 [TBL] [Abstract][Full Text] [Related]
13. Chemoresistance in Pancreatic Cancer. Zeng S; Pöttler M; Lan B; Grützmann R; Pilarsky C; Yang H Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514451 [TBL] [Abstract][Full Text] [Related]
14. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ahmad SA; Duong M; Sohal DPS; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS Ann Surg; 2020 Sep; 272(3):481-486. PubMed ID: 32740235 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG; JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170 [TBL] [Abstract][Full Text] [Related]
17. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. Janssen QP; van Dam JL; Bonsing BA; Bos H; Bosscha KP; Coene PPLO; van Eijck CHJ; de Hingh IHJT; Karsten TM; van der Kolk MB; Patijn GA; Liem MSL; van Santvoort HC; Loosveld OJL; de Vos-Geelen J; Zonderhuis BM; Homs MYV; van Tienhoven G; Besselink MG; Wilmink JW; Groot Koerkamp B; BMC Cancer; 2021 Mar; 21(1):300. PubMed ID: 33757440 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Sohal DPS; Duong M; Ahmad SA; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS JAMA Oncol; 2021 Mar; 7(3):421-427. PubMed ID: 33475684 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Motoi F; Unno M Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290 [TBL] [Abstract][Full Text] [Related]
20. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]